Peel Hunt Expects Full-Year Revenues and Profits to Beat Market Expectations

Peel Hunt upgrades guidance: strong M&A and equity capital markets activity drive revenues and profits ahead of expectations. A positive signal for UK mid-caps.

Hide Me

Written By

Joshua
Reading time
» 5 minute read 🤓
Share this

Unlock exclusive content ✨

Just enter your email address below to get access to subscriber only content.
Join 121 others ⬇️
Written By
Joshua
READING TIME
» 5 minute read 🤓

Un-hide left column

Peel Hunt raises the bar: revenues and profits to beat expectations

Peel Hunt has delivered a neat mid-year surprise. In a short but punchy RNS, the AIM-listed investment bank says it now expects full-year revenues and profits to come in ahead of current market expectations. The catalyst: strong second-half trading, with deal activity across M&A (mergers and acquisitions) and equity capital markets, plus continued momentum in its Execution Services business.

No hard numbers yet, but the direction of travel is clear – things are going better than analysts had pencilled in.

What’s driving the upgrade: deal flow and execution strength

The company highlights two engines of growth:

  • Investment Banking – supporting clients on a range of M&A and equity capital markets (ECM) transactions. ECM covers activities like IPOs, placings and secondary fundraisings.
  • Execution Services – Peel Hunt’s trading and liquidity provision to institutions and counterparties, helping grease the wheels of the UK market.

Crucially, Peel Hunt says it has traded well in the second half of the financial year. That implies H2 conditions improved versus H1, with better deal execution and trading volumes. For a broker focused on UK mid-cap and growth companies, that’s a constructive read-across for the broader market too – activity is picking up.

Why this matters for investors in AIM-listed PEEL

When a company says it’s trading “ahead of expectations”, it usually means analysts’ consensus forecasts are too low. That’s positive for sentiment and often a share price catalyst. It also suggests the firm’s fee pipeline (advice, capital raisings, M&A) is converting and that trading revenues are holding up.

For UK market watchers, the update hints at a healthier environment for corporate activity – not a boom, but better than the lull of recent years. If ECM and M&A are flowing, Peel Hunt’s model tends to benefit through both advisory fees and follow-on trading revenues.

What’s not disclosed today (and why that’s fine)

This is a guidance upgrade without numbers. Peel Hunt has not disclosed:

  • Revenue or profit figures – not disclosed.
  • The size of the beat versus consensus – not disclosed.
  • Transaction details (deal names, fees, volumes) – not disclosed.

That restraint is typical mid-period. The company has set a clear waypoint: it will announce revenues for FY26 on 1 April 2026. Expect a fuller breakdown then. For now, the key takeaway is the direction – up and to the right.

Key dates and details you can bank on

Guidance FY revenues and profits ahead of current market expectations
Trading comment Continued to trade well in the second half
Drivers M&A and equity capital markets transactions; Investment Banking and Execution Services strength
Next milestone FY26 revenues announcement on 1 April 2026
Listing AIM: PEEL
Client focus UK mid-cap and growth companies
Footprint London, New York, Copenhagen, Abu Dhabi

A quick explainer of the jargon

  • ECM (Equity Capital Markets): Raising equity for companies – IPOs, placings, rights issues and related advisory.
  • M&A: Advising on mergers and acquisitions – buyside, sellside and related financing.
  • Execution Services: Trading and market-making activities that provide liquidity to institutions in UK equities.
  • “Ahead of expectations”: Management believes actual results will exceed the current average of analysts’ forecasts.
  • UK MAR Article 17: When information is price-sensitive, companies must disclose it promptly. Calling this “inside information” signals materiality.

My take: a tidy, confidence-building update

It’s a clean, upbeat statement. Two things stand out. First, referencing both Investment Banking and Execution Services suggests the beat isn’t a one-trick pony – fee income and trading revenue are both contributing. Second, highlighting H2 strength implies momentum is recent, which matters if you’re trying to gauge the run-rate into FY27.

For a business geared to UK mid-caps, this reads like a modest cyclical turn. If the deal calendar is reopening and secondary fundraisings are happening, Peel Hunt’s Corporate and Broking franchise typically benefits via ongoing client mandates and repeat activity.

Balanced view: the positives and the watch-outs

Reasons to be positive

  • Upgrade on both revenues and profits – a stronger overall picture than a top-line-only beat.
  • Momentum in H2 across multiple franchises, hinting at healthier market conditions.
  • Clear near-term catalyst on 1 April 2026 for fuller disclosure.

Risks and variables to monitor

  • Market-sensitive model: deal flow and trading volumes can be lumpy and macro-dependent.
  • No quantum of the beat: without consensus context, it’s impossible to size the upgrade today.
  • Mix matters: the margin impact depends on the balance between advisory fees and lower-margin execution revenues.

What to watch between now and 1 April

  • Deal announcements across UK mid-caps – new placings, secondary fundraisings or M&A mandates.
  • Trading conditions in UK equities – liquidity, volatility and volumes that influence execution revenues.
  • Any commentary from sector peers that corroborates improving market activity.

Bottom line for retail investors

This is a classic “trading ahead” RNS, and it’s the kind investors like to see. While the numbers will have to wait until 1 April, Peel Hunt’s message is that both sides of the house – advisory and trading – are performing well into year-end. If that momentum holds, consensus likely needs to move up.

It’s not a victory lap, but it is a meaningful step in the right direction for an AIM-listed broker tethered to the fortunes of UK mid-caps. The next update should fill in the blanks; for now, the tone is upbeat and the trajectory is better than expected.

Disclaimer: This Blog is provided for general information about investments. It does not constitute investment advice. Information is taken from publicly available sources and any comment is that of the author who does not take any third party comment in the publication.
Last Updated

January 30, 2026

Category
Views
0
Likes
0

You might also enjoy 🔍

Minimalist digital graphic with a yellow-orange background, featuring 'Investing' in bold white letters at the centre and the 'Joshua Thompson' logo below.
Author picture
RUA Life Sciences pivots to commercial success: revenue doubled and EBITDA turns positive in final results, driven by CDMO growth and a strategic European acquisition.
This article covers information on RUA Life Sciences PLC.
Minimalist digital graphic with a yellow-orange background, featuring 'Investing' in bold white letters at the centre and the 'Joshua Thompson' logo below.
Author picture
Stelrad’s adjusted operating profit rose 3% to £32.5m in 2025, with margins expanding to 11.6% amid softer market demand and lower volumes.
This article covers information on Stelrad Group PLC.

Comments 💭

Leave a Comment 💬

No links or spam, all comments are checked.

First Name *
Surname
Comment *
No links or spam - will be automatically not approved.

Got an article to share?